Asha B. Pillai, M.D., FAAP, FABIM
- Associate Professor
- Associate Professor of Pediatrics and Microbiology & Immunology Deputy Director of Translational Research, Department of Pediatrics Co-Director, FOCIS Center of Excellence in Human Immunology, UMHC Member, Tumor Biology Program, Sylvester Comprehensive Cancer Center, UM
The Pillai group was first to discover innate-adaptive networks inducing histocompatibility-mismatched stem cell transplant (SCT) tolerance, defining the role of invariant natural killer T cells (iNKT cells) in setting up myeloid and Foxp3+Tregulatory cell activity and regulating GVHD while maintaining graft-versus-tumor activity (GVT). This has successfully translated to novel SCT techniques for children and adults nationally. The group is developing novel haplo-SCT strategies and iNKT immunotherapies for cancer, infectious diseases, and autoimmunity.